• Strong revenue growth of 17% and EBITDA growth of 10%
• Improving earnings per share and disciplined cost control
• On track to achieve full-year EBITDA guidance of A$1.87 to A$1.95 billion

Sonic Healthcare Limited (ASX: SHL; ADR: SKHHY) today reported a solid financial and operational performance for the half-year ended 31 December 2025. The company achieved strong revenue growth of 17%, EBITDA growth of 10%, and an 11% increase in net profit. Cash generated from operations grew by 10%, and earnings per share increased by 8%. Sonic Healthcare is on track to achieve its full-year EBITDA earnings guidance of A$1.87 to A$1.95 billion on a constant currency basis, provided in August 2025. The company's operations across its global footprint delivered strong organic growth, with the German business and Australian laboratory operations performing particularly well. While the US business has been impacted by low organic growth and restructuring costs, Sonic Healthcare has multiple initiatives underway to drive future revenue growth and enhance profitability, including expanding its advanced diagnostics product offering nationally. The company's radiology division continued its strong organic revenue growth, and the Sonic Clinical Services division achieved 20% earnings growth. Sonic Healthcare's well-established Medical Leadership culture remains a key competitive differentiator, and the company is focused on organic revenue growth, efficiency, innovation, and disciplined capital management to deliver sustainable long-term value for shareholders.

Sonic Healthcare is on track to achieve its full-year EBITDA earnings guidance of A$1.87 to A$1.95 billion on a constant currency basis, provided in August 2025.

Sonic Healthcare is confident in its ability to deliver sustainable long-term value for shareholders, with a focus on organic revenue growth, efficiency, innovation, and disciplined capital management.